PropThink: Endocyte – A Safe Bet for 2013

[ACN Newswire] – By David Sobek Endocyte (NASDAQ:ECYT) recently confirmed that the Marketing Authorization Application (MAA) filing process for vintafolide and etarfolatide in Europe is set to be completed by the end of … more

View todays social media effects on MRK

View the latest stocks trending across Twitter. Click to view dashboard